Abstract: The present invention relates to a technology for preventing or treating virus infection and infectious disease by inducing a mixed tailing regarding an RNA virus.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising miR-324 and TUT4/7 expression modulators, wherein the pharmaceutical composition of the present invention can prevent cell division and hinder cancer development by inhibiting the function of TUT4/7, and can increase the amount of miR-324-5p and suppress the function of miR-324-3p.1, and therefore can be effectively used for prevention, treatment, or diagnosis of cancer.

Abstract: The present disclosure provides a new protocol for sequencing the 3? end of messenger RNA (mRNA). The present disclosure can be very favorably used in analyzing the repetitive sequences of nucleic acids, which are difficult to analyze by current sequencing methods, especially, homopolymeric sequences (poly[A] sequence) of mRNA. The present disclosure has significantly improved sensitivity to mRNA compared with an existing method, thereby obtaining a lot of genetic information from a small amount of sample. The method of the present disclosure reduces the time and cost for sequencing the 3? end of mRNA and can be applied to various samples, and thus, can be used as a useful tool in the study of RNA synthesis/degradation and protein production in association with all life phenomena, including embryogenesis, cancer, and neurotransmission.

Abstract: The present disclosure provides a new protocol for sequencing the 3? end of messenger RNA (mRNA). The present disclosure can be very favorably used in analyzing the repetitive sequences of nucleic acids, which are difficult to analyze by current sequencing methods, especially, homopolymeric sequences (poly[A] sequence) of mRNA. The present disclosure has significantly improved sensitivity to mRNA compared with an existing method, thereby obtaining a lot of genetic information from a small amount of sample. The method of the present disclosure reduces the time and cost for sequencing the 3? end of mRNA and can be applied to various samples, and thus, can be used as a useful tool in the study of RNA synthesis/degradation and protein production in association with all life phenomena, including embryogenesis, cancer, and neurotransmission.

Abstract: The present invention relates to a phosphatidylinositol 3-kinases activity regulator which include the fifth zinc finger domain of FOG2 and which, more specifically, can induce cancer cells to die due to the inclusion of the fifth zinc finger domain of FOG2. Since the death of cancer cells is induced by suppressing the transfer of PI3K signals, the fifth zinc finger domain of FOG2 according to the present invention can be suitably use as a composition for the prevention and treatment of PI3K-related diseases.

Abstract: The present invention relates to a phosphatidylinositol 3-kinases activity regulator which include the fifth zinc finger domain of FOG2 and which, more specifically, can induce cancer cells to die due to the inclusion of the fifth zinc finger domain of FOG2. Since the death of cancer cells is induced by suppressing the transfer of PI3K signals, the fifth zinc finger domain of FOG2 according to the present invention can be suitably use as a composition for the prevention and treatment of PI3K-related diseases.

Abstract: The present invention relates to a miRNA regulating the insulin signaling pathway, and to a method for screening a material for controlling the action of a target gene thereof, and particularly, to a method for screening a material for controlling the action of USH or FOG2, a target gene of miR-8 or miR-200 miRNA for promoting cell growth. The present inventors discovered miR-8, a conserved miRNA for regulating the body of a fruit fly by targeting u-shaped material (USH) in the fat cells of Drosophila. It was also confirmed that a target gene of miR-200, a human homologous gene of Drosophila miR-8 miRNA, is FOG2. It was found that Drosophila miR-8 and USH are also conserved in mammals, and FOG2, a human homologous gene of USH, directly binds to a regulating subunit of PI3K and functions. It was confirmed that when the expression of miR-200 is inhibited or FOG2 is expressed in a human cancer cell line, the activity of PI3K, which promotes cell growth, is decreased.

Abstract: The present invention relates to an amphiphilic peptide capable of promoting target miRNA production and a method for regulating the production of target miRNA using the same. In detail, the amphiphilic peptide of the present invention binds strongly and specifically to hairpin-shaped target miRNA. The specific binding affinity induces the Dicer enzyme activity, therefore specifically increase the production of target miRNA. The present invention can be effectively used for regulating the amount of target miRNA produced in vivo, for the study of miRNA functions and for producing therapeutic drug for target miRNA related disease.

Abstract: A method of producing a replication defective retrovirus comprising transfecting a producer cell with the following: iii) a retroviral genome; iv) a nucleotide sequence coding for retroviral gag and pot proteins; and iii) nucleotide sequences encoding other essential viral packaging components not encoded by the nucleotide sequence of (ii); characterised in that the nucleotide sequence coding for retroviral gag and pot proteins is codon optimised for expression in the producer cell.

Abstract: A viral vector production system is provided which system comprises: (i) a viral genome comprising at least one first nucleotide sequence encoding a gene product capable of binding to and effecting the cleavage, directly or indirectly, of a second nucleotide sequence, or transcription product thereof, encoding a viral polypeptide required for the assembly of viral particles; (ii) a third nucleotide sequence encoding said viral polypeptide required for the assembly of the viral genome into viral particles, which third nucleotide sequence has a different nucleotide sequence to the second nucleotide sequence such that said third nucleotide sequence, or transcription product thereof, is resistant to cleavage directed by said gene product. The viral vector production system may be used to produce viral particles for use in treating or preventing viral infection.

Abstract: The present invention relates to novel miRNA molecules, more particularly to novel miRNA molecules isolated from human embryonic stem cells. The miRNA molecules provided by the present invention can be usefully used as a molecular marker for early developmental stages of undifferentiated human embryonic stem cells. Also, the miRNA molecules of the present invention may play an important role in the regulation of mammalian embryonic stem cells. Therefore, the miRNA molecules can be usefully used for analyzing regulatory networks of human embryonic stem cells.

Abstract: Retroviral vector production systems for producing lentivirus-based vector particles which are capable of infecting and transducing non-dividing target cells, wherein one or more of the auxiliary genes such as vpr, vif, tat, and nef in the case of HIV-1 are absent from the system. The systems and resulting retrovirus vector particles have improved safety over existing systems and vectors.

Abstract: A method of producing a replication defective retrovirus comprising transfecting a producer cell with the following: iii) a retroviral genome; iv) a nucleotide sequence coding for retroviral gag and pol proteins; and iii) nucleotide sequences encoding other essential viral packaging components not encoded by the nucleotide sequence of (ii); characterised in that the nucleotide sequence coding for retroviral gag and pol proteins is codon optimised for expression in the producer cell.

Abstract: The present invention relates to novel miRNA molecules, more particularly to novel miRNA molecules isolated from human embryonic stem cells. The miRNA molecules provided by the present invention can be usefully used as a molecular marker for early developmental stages of undifferentiated human embryonic stem cells. Also, the miRNA molecules of the present invention may play an important role in the regulation of mammalian embryonic stem cells. Therefore, the miRNA molecules can be usefully used for analyzing regulatory networks of human embryonic stem cells.

Abstract: Retroviral vector production systems for producing lentivirus-based vector particles which are capable of infecting and transducing non-dividing target cells, wherein one or more of the auxiliary genes such as vpr, vif, tat, and nef in the case of HIV-1 are absent, from the system. The systems and resulting retrovirus vector particles have improved safety over existing systems and vectors.

Abstract: Retroviral vector production systems for producing lentivirus-based vector particles which are capable of infecting and transducing non-dividing target cells, wherein one or more of the auxiliary genes such as vpr, vif, tat, and nef in the case of HIV-1 are absent from the system. The systems and resulting retrovirus vector particles have improved safety over existing systems and vectors.

Abstract: A retroviral vector derived from a non-primate lentivirus genome comprising a deleted gag gene wherein the deletion in gag removes one or more nucleotides downstream of nucleotide 350 of the gag coding sequence.

Abstract: A selection system suitable for use in vivo is provided, the system comprising: I) a plurality of first nucleotide sequences encoding a gene product capable of binding to and effecting the cleavage, directly or indirectly, of a nucleotide sequence, or a transcription product thereof; wherein a region of the first nucleotide sequence required for binding to the nucleotide sequence is heterogeneous within the plurality of first nucleotide sequences; and ii) a second nucleotide sequence comprising: (a) a coding region encoding a detectable marker operably linked to sequences required for mRNA stability and/or translation; and (b) a third nucleotide sequence positioned between the coding region and at least one of the sequences required for mRNA stability and/or translation; wherein (a) and (b) are operably linked to a regulatory sequence capable of directing expression of (a) and (b) as a contiguous RNA molecule in a host cell; and wherein the first nucleotide sequence encoding a gene product is capable of bindi

Abstract: Provided herein are methods for producing a replication defective retrovirus, which comprises transfecting a producer cell with (1) a retroviral genome; (2) a nucleotide sequence coding for retroviral gag and pol proteins that is codon-optimized for expression in the producer cell; and (3) nucleotide sequences encoding other essential viral packaging components not encoded by the nucleotide sequence of (1).

Abstract: Retroviral vector production systems for producing lentivirus-based vector particles which are capable of infecting and transducing non-dividing target cells, wherein one or more of the auxiliary genes such as vpr, vif, tat, and nef in the case of HIV-1 are absent from the system. The systems and resulting retrovirus vector particles have improved safety over existing systems and vectors.